Nanomedicine News

RSS

Nanoformulated Protease Inhibitor Paves Way for Effective HIV Treatment

Protease inhibitors are a class of antiviral drugs that are commonly used to treat HIV, the virus that causes AIDS. Scientists at the University of Nebraska Medical Center designed a new delivery system for these drugs that, when coupled with a drug developed at the University of Rochester School of Medicine and Dentistry, rid immune cells of HIV and kept the virus in check for long periods. The results appear in the journal Nanomedicine: Nanotechnology, Biology and Medicine.

20 Oct 2015

Cerulean Provides Update on Clinical Trial Exploring Dose-Intensive Schedule for CRLX101 Nanoparticle-Drug Conjugate

Cerulean Pharma Inc., a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in a trial exploring a dose-intensive schedule for its lead NDC, CRLX101, in patients with advanced solid tumor malignancies.

20 Oct 2015

Archaeal Gas Vesicle Nanoparticles Hold Potential to Develop Powerful Malaria Vaccine

In a recent breakthrough to combat malaria, a collaboration of Indian and American scientists have identified a malarial parasite protein that can be used to develop antibodies when displayed on novel nanoparticles.

20 Oct 2015

Nanomaterials Show Promise to Advance Therapeutic Dentistry

Have a cavity? Ask your dentist about filling it with a mixture of nanoparticles including silica and zirconia. These white fillings (known as nano-composite resins) resemble teeth better than their metal alternatives and are less likely to come loose or fracture teeth.

20 Oct 2015

Orfit’s HP PRO SOLUTION and Nanor® Immobilization Masks Together Provide Improved Patient Comfort

At the ASTRO 57th Annual Meeting & Exhibition in San Antonio, Texas, Orfit Industries will proudly introduce and demonstrate its "HP PRO SOLUTION", an innovative, comprehensive and versatile immobilization system for use in proton therapy designed for Brain, Head and Neck treatments in proton therapy. The "HP PRO SOLUTION" has received U.S. Food and Drug Administration 510 (k) clearance.

19 Oct 2015

Selecta Presents New Advancements at the American Society for Nanomedicine Annual Meeting

Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, announced today that its Chief Scientific Officer, Takashi Kei Kishimoto, PhD, presented new advancements related to Selecta’s pipeline of novel immunotherapeutic candidates at the 5th Annual American Society for Nanomedicine Meeting in Crystal City, Virginia.

19 Oct 2015

Enrollment Complete in Cerulean CRLX101 NDC-Avastin Combination Phase 2 Trial in RCC

Cerulean Pharma Inc., a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced completion of enrollment of a randomized Phase 2 trial of its lead NDC, CRLX101, in combination with Avastin®, in third- and fourth-line relapsed renal cell carcinoma (RCC). The trial has enrolled all 110 patients and the company expects to announce top-line data in the first half of 2016.

16 Oct 2015

Matinas BioPharma to Provide Update on MAT2203 Phase 2a Clinical Study at 14th Annual BIO Investor Forum

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the 14th Annual BIO Investor Forum being held October 20-21, 2015, at the Parc 55 in San Francisco, California.

15 Oct 2015

Nanomedical Diagnostics Completes $1.6 Million Series A Financing Round

Nanomedical Diagnostics, a biotech company developing and commercializing bioelectronics for use in research and diagnostics, announces the completion of a Series A financing round of $1.6 million led by Serra Ventures.

15 Oct 2015

Laser-Based Stimulated Raman Scattering Microscopy Could Help Differentiate Between Tumor Tissue and Normal Brain

Brain tumor tissue can be hard to distinguish from normal brain during surgery. Neurosurgeons use their best judgment in the operating room but often must guess exactly where the edges of the tumor are while removing it.

15 Oct 2015

Nanomedicine News

Nanoformulated Protease Inhibitor Paves Way for Effective HIV Treatment

Cerulean Provides Update on Clinical Trial Exploring Dose-Intensive Schedule for CRLX101 Nanoparticle-Drug Conjugate

Archaeal Gas Vesicle Nanoparticles Hold Potential to Develop Powerful Malaria Vaccine

Nanomaterials Show Promise to Advance Therapeutic Dentistry

Orfit’s HP PRO SOLUTION and Nanor® Immobilization Masks Together Provide Improved Patient Comfort

Selecta Presents New Advancements at the American Society for Nanomedicine Annual Meeting

Enrollment Complete in Cerulean CRLX101 NDC-Avastin Combination Phase 2 Trial in RCC

Matinas BioPharma to Provide Update on MAT2203 Phase 2a Clinical Study at 14th Annual BIO Investor Forum

Nanomedical Diagnostics Completes $1.6 Million Series A Financing Round

Laser-Based Stimulated Raman Scattering Microscopy Could Help Differentiate Between Tumor Tissue and Normal Brain

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Gold Nanoparticles to Restore Vision in Retinal Disorders

Levidian and Zentek Seek to Establish Graphene-Integrated Filter Manufacturing Facility in the Middle East to Advance Cleaner, Safer Air

Scalable Method for Porous Graphene Membranes for CO2 Capture

New Nanocage Material Removes Up to 90% of Toxic PFAS from Water

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting